Aquinox Announces Topline Results of Phase 3 LEADERSHIP 301 Clinical Trial in Interstitial…
Aquinox Pharmaceuticals announced that the Phase 3 LEADERSHIP 301 clinical trial evaluating once-daily, oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain…
Read More...
Read More...
